Q-omics provides the consensus-scored MIR624 profile across patient tissues and cancer cell-line models. MIR624 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in TGCT. Additionally, MIR624 RNA expression shows 6,368 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, and STAD as cancer lineages where MIR624 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.